Reversal of Eliquis (Apixaban) in Subarachnoid Hemorrhage
Administer andexanet alfa as the first-line reversal agent for apixaban-associated subarachnoid hemorrhage, using a weight-based bolus followed by a 2-hour infusion. 1
Primary Reversal Strategy
Andexanet alfa is the FDA-approved specific reversal agent for apixaban and should be your immediate choice. The drug works by binding to factor Xa inhibitors, rapidly reducing anti-FXa activity by approximately 93% within minutes 1. In the ANNEXA-4 study, 80% of patients with major bleeding (69% intracranial hemorrhages) achieved excellent or good hemostatic efficacy at 12 hours 1.
Dosing Protocol
- Low-dose regimen: For apixaban ≤5 mg taken >8 hours ago or unknown timing
- High-dose regimen: For apixaban >5 mg or ≤5 mg taken <8 hours ago
- Administer as IV bolus over 15-30 minutes followed by 2-hour continuous infusion 1
Alternative Reversal Options
If andexanet alfa is unavailable or contraindicated, use 4-factor prothrombin complex concentrate (4F-PCC) at 50 units/kg 2. While 4F-PCC lacks specific FDA approval for DOAC reversal, the 2016 Neurocritical Care Society guidelines conditionally recommend it for factor Xa inhibitor-associated intracranial hemorrhage when the drug was taken within 3-5 terminal half-lives 2. Recent data shows 73.7% of DOAC-treated patients achieved excellent/good hemostatic efficacy with 4F-PCC, comparable to warfarin reversal 3.
Do not use:
- Recombinant factor VIIa or fresh frozen plasma as primary reversal agents 2
- Protamine sulfate or vitamin K (ineffective against apixaban) 4
- Monitoring with PT, INR, aPTT, or anti-FXa levels to guide reversal (unreliable for apixaban) 4
Critical Management Considerations
Timing is Essential
- Apixaban's anticoagulant effect persists for at least 24 hours after the last dose (approximately two half-lives) 4
- Administer reversal immediately upon diagnosis—do not wait for laboratory confirmation
- The pharmacodynamic effect of 4F-PCC peaks at 4 hours but creates a prothrombotic state lasting up to 69 hours 4
Thrombotic Risk Warning
This is the major pitfall: Both andexanet alfa and 4F-PCC carry significant thrombotic complications. In ANNEXA-4,10% of patients experienced thrombotic events, with 16 occurring despite prophylactic anticoagulation 1. The ANNEXA-I trial showed increased thromboembolic events with andexanet alfa compared to usual care 1. Most thrombotic events occurred in patients who did not resume anticoagulation 1.
Adjunctive Measures
- Activated charcoal: Administer if apixaban was taken within 2-4 hours (reduces absorption) 4
- Hemodialysis: Not effective for apixaban removal 4
- Tranexamic acid or desmopressin: No clinical experience with apixaban; not recommended 4
Post-Reversal Management
After achieving hemostasis, you face a critical decision about anticoagulation resumption. The 30-day thrombotic risk after reversal is 4.8%, with most events in patients whose anticoagulation was not restarted 1. Balance the hemorrhage risk against the stroke/thrombosis risk based on:
- Hemorrhage stability on repeat imaging
- Original indication for anticoagulation (atrial fibrillation with high CHA₂DS₂-VASc score carries substantial stroke risk)
- Neurosurgical input on hemorrhage etiology
Consider restarting anticoagulation at 7-14 days if hemorrhage is stable and thrombotic risk is high, though this requires individualized neurosurgical consultation.
Key Pitfalls to Avoid
- Delaying reversal for laboratory confirmation: Treat based on history and imaging
- Using coagulation tests to monitor reversal: PT, INR, aPTT are unreliable for apixaban 4
- Failing to anticipate thrombotic complications: Monitor closely for 30 days post-reversal
- Never restarting anticoagulation: Increases thrombotic risk substantially 1
The evidence strongly supports andexanet alfa as first-line therapy 1, with 4F-PCC as a reasonable alternative when andexanet is unavailable 2, 3. Both carry thrombotic risks that must be weighed against the immediate hemorrhagic emergency.